Verona Pharma Dropped from S&P Global BMI Index

Verona Pharma plc (VRNA) has been dropped from the S&P Global BMI Index. The biopharmaceutical company focuses on developing therapeutics for respiratory diseases and is currently developing ensifentrine, a treatment for chronic obstructive pulmonary disease (COPD), in various formulations.

Verona Pharma plc (VRNA), a biopharmaceutical company specializing in respiratory disease therapies, has been removed from the S&P Global BMI Index. The company focuses on developing ensifentrine, a treatment for chronic obstructive pulmonary disease (COPD), in various formulations. Despite its recent acquisition by Merck & Co., Inc. for $10 billion, VRNA's exclusion from the index reflects broader market dynamics and investor sentiment Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[1] Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[2].

Verona Pharma's lead product, Ohtuvayre (ensifentrine), received FDA approval in June 2024 and has seen rapid adoption since its launch. The drug combines bronchodilator and anti-inflammatory effects, offering significant benefits to COPD patients. The company's strong financial momentum is evident, with Q1 2025 net revenues reaching $76.3 million, nearly double Q4 2024, driven primarily by Ohtuvayre sales Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[1] Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[2].

The acquisition by Merck & Co., Inc. is expected to close on October 7, 2025, pending final UK court approval. This deal strengthens Merck's (MRK) respiratory portfolio ahead of upcoming patent expirations on Keytruda, with Ohtuvayre providing a high-growth addition. VRNA's management highlighted that Merck's commercial and clinical capabilities will accelerate the drug's reach to COPD patients, while Ohtuvayre is also being evaluated for non-cystic fibrosis bronchiectasis in ongoing trials Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[1] Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio^[2].

While the removal from the S&P Global BMI Index may signal a shift in market perception, it is essential to note that Verona Pharma continues to generate strong financial performance. The company's focus on innovative respiratory therapies and its strategic partnership with Merck position it for future growth. Investors should closely monitor the company's progress and the ongoing trials for Ohtuvayre to assess its long-term potential.